Homko Carol J, Zamora Linda C, Kerper Margaret M, Mozzoli Maria, Kresge Karen, Boden Guenther
Clinical Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania.
J Prim Care Community Health. 2012 Oct 1;3(4):235-8. doi: 10.1177/2150131911435526. Epub 2012 Feb 11.
In 2010, the American Diabetes Association revised its criteria for the diagnosis of diabetes to include A1C ≥ 6.5%; however, this has remained controversial, particularly for African Americans. The objective of this pilot study was to examine the usefulness of a single A1C determination in comparison with a same day 2-hour oral glucose tolerance test to diagnose type 2 diabetes in African Americans.
In sum, 195 oral glucose tolerance tests and A1Cs were obtained on the same day from 77 overweight and obese African American women and 6 men over a period of 15 months.
A1C ≥ 6.5% was present in 31 of 195 patients, with 15 of these having type 2 diabetes by oral glucose tolerance test, another 12 having impaired glucose tolerance, and 4 having normal glucose tolerance. This gives a sensitivity of 50% and a specificity of 90%, with a positive predictive value of 48% and a negative predictive value of 91%. A1C ≤ 5.6%, proposed by the American Diabetes Association to indicate normal glucose tolerance, was present in only 28 patients, 10 (35.7%) of whom had normal glucose tolerance, whereas 18 (64.3%) had either impaired glucose tolerance (15 patients) or type 2 diabetes (3 patients). Fasting plasma glucose ≥ 126 mg/dL was present in 5 of 29 patients with type 2 diabetes (sensitivity, 17.2%; specificity, 100%).
First, A1C ≥ 6.5% was a good "rule in" value to identify impaired glucose tolerance and type 2 diabetes (ie, patients at high risk for micro- and macrovascular complications). Second, A1C ≤ 5.6% did not rule out impaired glucose tolerance or type 2 diabetes. Last, fasting plasma glucose ≥ 126 mg/dL detected less than 1 in 5 cases with type 2 diabetes.
2010年,美国糖尿病协会修订了糖尿病诊断标准,将糖化血红蛋白(A1C)≥6.5%纳入其中;然而,这一标准仍存在争议,尤其是在非裔美国人中。本试点研究的目的是比较单次A1C测定与同日2小时口服葡萄糖耐量试验在诊断非裔美国人2型糖尿病方面的有效性。
在15个月的时间里,从77名超重和肥胖的非裔美国女性及6名男性中,同日获取了195份口服葡萄糖耐量试验和A1C检测结果。
195例患者中有31例A1C≥6.5%,其中15例经口服葡萄糖耐量试验诊断为2型糖尿病,12例为糖耐量受损,4例糖耐量正常。其敏感性为50%,特异性为90%,阳性预测值为48%,阴性预测值为91%。美国糖尿病协会提出的A1C≤5.6%用于表示糖耐量正常,仅28例患者符合此标准,其中10例(35.7%)糖耐量正常,而18例(64.3%)患有糖耐量受损(15例)或2型糖尿病(3例)。29例2型糖尿病患者中有5例空腹血糖≥126mg/dL(敏感性为17.2%,特异性为100%)。
首先,A1C≥6.5%是识别糖耐量受损和2型糖尿病(即微血管和大血管并发症高危患者)的良好“纳入”值。其次,A1C≤5.6%不能排除糖耐量受损或2型糖尿病。最后,空腹血糖≥126mg/dL在2型糖尿病患者中检出率不到五分之一。